文献速递肺外科

新辅助化免疫治疗后非小细胞肺癌微创切除的多中心研究

Minimally invasive resection of non-small cell lung cancer after chemoimmunotherapy: A multicenter study in academic hospitals.
PubMed 文献 · J Thorac Cardiovasc Surg · 2025-07-25

该多中心研究纳入2019至2024年间美国与德国5个中心207例接受新辅助化免疫治疗后切除的非小细胞肺癌患者,其中164例(79.2%)行微创手术,43例(20.8%)行开放切除。微创手术更常用于肺叶切除,且与更短住院时间和更少主要并发症相关,病理完全缓解是微创手术的独立预测因素。

要点

  • 新辅助化免疫治疗后多数患者可行微创手术,病理完全缓解者微创可能性更高。
  • 微创手术R0切除率98.2%,高于开放手术的88.4%。
  • 微创手术住院时间更短(调整中位3天 vs 7天),主要并发症更少。

核心结论

  • 新辅助化免疫治疗后多数非小细胞肺癌患者可行微创手术,尤其病理完全缓解者,微创手术与高完全切除率和快速康复相关。
  • 开放手术更多用于残留大肿瘤或需扩大切除的患者。

研究设计与样本

  • 多中心回顾性研究,合并美国与德国5个中心2019至2024年接受新辅助化免疫治疗后切除的非小细胞肺癌患者数据,共207例。
  • 分析微创手术相关临床与病理因素,并比较微创与开放手术结局。

主要发现

  • 164例(79.2%)行微创手术,43例(20.8%)行开放切除。
  • 微创手术更常用于肺叶切除(93.9% vs 开放58.8%),较少用于双肺叶切除(2.6% vs 14.7%)或全肺切除(2.6% vs 26.5%,P < .0001)。
  • 机器人辅助手术中转开胸率低于电视辅助胸腔镜手术(4.5% vs 31%,P = .001)。
  • 开放手术更多用于较大残留肿瘤(ypT3/4:微创8.5% vs 开放32.5%,P = .0002)。
  • 病理完全缓解率39.1%,为微创手术独立预测因素(OR 10.81,95%CI 2.71-43.20,P = .001)。

关键数值与推荐

  • 微创手术与更短住院时间相关(调整中位3天 vs 7天,P < .0001)。
  • 微创手术主要并发症更少(9.1% vs 25.6%,P = .038)。
  • 60天死亡率为1%。

临床怎么用

  • 新辅助化免疫治疗后评估可切除的非小细胞肺癌患者,尤其病理完全缓解者,可优先考虑微创手术。
  • 对于残留大肿瘤(ypT3/4)或需扩大切除者,开放手术仍为常见选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We sought to analyze the outcomes of minimally invasive surgery and open resection of non-small cell lung cancer after neoadjuvant chemoimmunotherapy relative to treatment response. METHODS: Data from 5 centers in the United States and Germany were combined for all patients undergoing resection for non-small cell lung cancer after neoadjuvant chemoimmunotherapy between 2019 and 2024. Clinical and pathologic factors associated with minimally invasive surgery were analyzed. Minimally invasive surgery and open surgery outcomes were compared. RESULTS: A total of 207 patients were included, of whom 164 (79.2%) underwent minimally invasive surgery and 43 (20.8%) underwent open resection. Minimally invasive surgery was more commonly used for lobectomy (93.9% vs 58.8% open) and less frequently for bilobectomy (2.6% vs 14.7% open) or pneumonectomy (2.6% vs 26.5% open, P < .0001). Unplanned conversion to thoracotomy (9.1%, n = 15) occurred less often for robotic-assisted compared with video-assisted thoracoscopic surgery (4.5% vs 31%, P = .001). Open resection was used more often performed for larger residual tumors (ypT3/4, minimally invasive surgery 8.5% vs open 32.5%, P = .0002). A pathologic complete response in 39.1% of patients was an independent predictor of minimally invasive surgery (odds ratio, 10.81; 95% CI, 2.71-43.20; P = .001). Complete R0 resection was achieved in 96.1% of patients (minimally invasive surgery 98.2% vs open 88.4%, P = .003). Minimally invasive surgery was associated with shorter length of stay (adjusted median 3 days vs 7 days, P < .0001) and fewer major complications (9.1% vs 25.6%, P = .038). The 60-day mortality rate was 1%. CONCLUSIONS: Minimally invasive surgery is possible in most patients after neoadjuvant chemoimmunotherapy, especially after complete pathologic response, and is associated with high rates of complete resection and fast recovery. Open surgery is performed more often for patients with large residual tumors or those requiring extended resections.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Kneuertz PJ, Villamizar N, Altorki NK, et al. Minimally invasive resection of non-small cell lung cancer after chemoimmunotherapy: A multicenter study in academic hospitals. J Thorac Cardiovasc Surg. 2025. PMID: 40716726. doi:10.1016/j.jtcvs.2025.07.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。